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ABSTRACT
Objectives Meta- analysis based on individual patient 
data (IPD) from randomised trials is superior to using 
published summary data since it facilitates subgroup 
and multiple variable analyses. Guidelines and funders 
expect that researchers share IPD for bona fide analyses, 
but in practice, this is done variably. Here, we report the 
experience of obtaining IPD for two collaborative analysis 
studies.
Setting Two linked studies required IPD from published 
randomised trials. The leading researchers for eligible 
trials were approached and asked to share IPD including 
trial characteristics, patient demographics, baseline clinical 
data and outcome measures.
Participants Participants in eligible randomised controlled 
trials included patients with or at risk of cognitive decline/
vascular events.
Primary and secondary outcome measures Numbers 
(%) of trials where the leading researcher responded 
favourably/negatively or did not respond. If negative, 
reasons behind the response were collected. If positive, 
methods used to share IPD were recorded.
Results Across the two studies, 391 completed trials 
were identified. Email addresses for researchers were 
found for 313 (80%) of the trials. One hundred and forty- 
eight (47%) researchers did not respond despite being 
sent multiple emails. Following contact, positive initial 
responses were received from 92 researchers, resulting 
in IPD being shared for 78 trials. Eighty- seven (28%) 
researchers declined to share data; justifications were 
recorded. The median time from first request to accessing 
data in one study was 241 (IQR 383.3) days. IPD sources 
included: direct from researcher, via academic trial funders 
repository and a website requiring remote analysis of 
commercial data. Where data were shared, a variety of 
methods were used to transfer data.
Conclusion Sharing of IPD from trials is desirable and a 
requirement of many funding bodies. However, accessing 
IPD faces multiple challenges including refusals to share, 
delays in access to data and having to perform analyses 
on a remote website.
Trial registration Not applicable.
INTRODUCTION
The purpose of clinical research is to improve 
treatment and outcomes for patients, but 
also to do so ethically and efficiently, with 
the minimum possible number of patients 
subjected to experimental treatments in trials. 
Sharing of individual patient data (IPD) can 
allow multiple questions to be answered using 
the same data, thus preventing the unneces-
sary exposure of further patients to exper-
imental treatments. There is an increasing 
expectation that researchers should share trial 
data when requested. Funding bodies such 
as the US National Institutes of Health and 
UK Medical Research Council1 2 now require 
researchers to agree to share data before 
funding is granted. Further, the International 
Committee of Medical Journal Editors3 also 
now require researchers to indicate their 
intention to share data in order for the trial 
paper to be published, as promoted by jour-
nals such as the British Medical Journal and 
Public Library of Science (PLoS) journals.4 5 With 
respect to commercial trials, some sponsors 
openly share their trial data.6–8 However, even 
with these policies in place, investigators may 
still face challenges in accessing IPD.9 In a 
survey of academics who were corresponding 
authors for clinical trials, 88% said that they 
Strengths and limitations of this study
 ► Both studies identified a large number of eligible tri-
als across two separate disease areas, resulting in a 
large number of researchers being contacted.
 ► Trials included had academic and commercial spon-
sors, no restriction on country of origin and covered 
a wide timeframe (1985 to 2017).
 ► Results are likely to reflect a common experience 
in data sharing in vascular and dementia research.
 ► A limitation of this work is that only email or let-
ter was used to contact authors due to available 
resources.
 ► It was not possible to survey non- responders to data 
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were in favour of data sharing, with 75% believing that 
it should be mandatory.10 However, only 18% of the 
researchers surveyed said their funder required them 
to share their data and of these, only 57% had actually 
shared data.10
The Stroke Trials Unit at the University of Nottingham 
has coordinated several studies that depend on pooled 
analyses of clinical or preclinical IPD: Optimising the 
Analysis of Acute Stroke Trials (OAST) collaboration,11–14 
Dipyridamole In Stroke Collaboration,15 16 Community 
Occupational Therapy for Stroke,17 NXY-059 for exper-
imental stroke18 and Progesterone for experimental 
stroke.19 None of these projects could obtain IPD for all 
included trials. Two further studies are ongoing: Opti-
mising the analysis of cognition collaboration (OA- Cog) 
and the Optimising the analysis of vascular prevention 
trials collaboration (OA- Prevention). These studies aim 
to identify the most efficient statistical techniques for 
analysing either cognition or vascular prevention data, 
respectively. Their analyses will be performed using IPD 
from randomised controlled trials involving patients with, 
or at risk of developing, either cognitive impairment or 
dementia, or vascular events such as stroke or myocardial 
infarction.
We report our experience of identifying and contacting 
chief investigators, and obtaining and analysing trial IPD 
for the OA- Cog and OA- Prevention studies.
METHODS
OA-Cog and OA-Prevention
Both studies finalised protocols and received research 
ethics committee waivers prior to commencing the data 
sharing phase. Strategies for identifying relevant trials 
and requesting IPD were similar and followed those 
used previously (OAST study).11–14 First, relevant trials 
were identified through searches of the Cochrane Data-
base of Systematic Reviews and PubMed using specific 
keywords related to the particular study (eg, OA- Cog 
‘Dementia’ and ‘Alzheimer’s disease’; OA- Prevention 
‘Stroke prevention’). The resulting outputs from these 
searches were then evaluated for relevance by PS and 
LJW. Detailed search strategies are not essential for 
this paper and will be reported as part of the individual 
studies.
Trials were eligible for inclusion if the primary analysis 
was statistically significant with a p value<0.05, showing 
either benefit or harm, or were included in a systematic 
review showing statistically significant benefit or harm 
overall. Trials were excluded if they were not randomised, 
were neutral (p≥0.05) within a neutral review, did not 
collect outcome data required in the studies (for OA- Cog 
this was global cognition score and for OA- Prevention 
severity of vascular event data) or met at least two of 
the following conditions: <50 participants; published 
before 1995; full publication of the primary analysis was 
unavailable.
Author contact
Once a trial was deemed eligible, the lead researcher or 
corresponding author was contacted by email, letter or 
via an online application form. If an email address was 
not provided in the trial publication or the email address 
was no longer active, attempts were then made to identify 
current contact information. Methods included internet 
searches for more recent publications by the same author, 
or for other authors from the primary publication, or by 
contacting the researcher’s institution as listed in the 
publication. If no response was received within 4 weeks, 
a reminder email was sent to the same email address. 
Reminders were sent up to four times with a minimum of 
4 weeks between each reminder.
Researchers were requested to share data on: patient 
demographics (eg, age, sex), medical history (eg, history 
of hypertension), baseline clinical data (eg, blood pres-
sure, stroke type, functional status), outcome measures 
(eg, global cognition scale score, quality of life, vascular 
events and event dates) and trial characteristics (eg, rando-
misation group, length of follow- up). Once received, the 
IPD were combined into one master database with each 
trial given a unique identifier.
Data sharing mechanisms
Multiple mechanisms exist for sharing data. IPD may be 
published within the main paper (only relevant if the 
trial has a small sample size), published directly on the 
web with open access, submitted by the lead researcher 
directly as a data file either by email or via USB/CD (typi-
cally with encryption to protect confidentiality), accessed 
through an academic collaboration data repository or on 
a website hosting both the trial data and statistical pack-
ages so that analyses have to be performed on the remote 
server.
Outcomes and statistical analyses
The main outcome for this analysis was receipt of IPD 
for inclusion in the OA- Cog and OA- Prevention studies. 
Other outcomes included response (positive or nega-
tive) and non- response rates. We compared the following 
trial characteristics between those that did or did not 
make IPD available: year of publication, sample size and 
sponsor type. We also collected reasons for not sharing 
IPD, where given. For OA- Prevention only, we collected 
data regarding time from initial contact date to receipt of 
trial data. Data are tabulated and shown as number and 
per cent or median with 25th and 75th centiles.
RESULTS
Identifying eligible trials
Of 391 trials identified as being relevant to the OA- Cog 
or OA- Prevention studies, an active email address for the 
lead researcher or a corresponding author was provided 
in the primary publication for 194 (50%, figure 1) and 
was either not given or inactive for 197 trials. Of the 197 
















pen: first published as 10.1136/bm






3Scutt P, et al. BMJ Open 2020;10:e038765. doi:10.1136/bmjopen-2020-038765
Open access
for 119 from secondary publications, other authors, the 
lead researcher’s institution or web searches. No email 
address was found for researchers of 78 trials. Invitation 
emails were sent to the lead researcher of the resulting 
313 trials. Thirteen trials were eligible for both studies; 
the lead researcher was contacted using a joint email for 
two of these trials.
Obtaining IPD
Of 313 invitations sent, we received positive initial 
responses from 92 researchers (29%), from whom 78 trial 
datasets were obtained. In spite of further reminders, 14 
researchers did not follow through on their initial willing-
ness to share data. One hundred and forty- nine (48%) 
researchers did not respond despite evidence that the 
email address was still in use and multiple reminders 
being sent. Eighty- six (27%) researchers declined to 
share their data (table 1); reasons included ‘operational 
constraints’, ‘non- availability of data’ and non- availability 
of the researcher (death, retirement, moved into another 
scientific field). Of the 13 trials who were contacted for 
both studies, four researchers responded positively and 
shared their data. However, four of the researchers did not 
respond at all to either of the studies and the remaining 
five agreed to share data with one study but not the other.
Timings
The median time from sending the first email to success-
fully receiving data in the OA- Prevention study was 242 
(25th, 75th centile: 21.5, 405) days. This varied between 
the different methods for sharing data and data source 
(commercial website/lead researcher/academic repos-
itory; figures 2 and 3). Time from initial contact to 
receiving a copy of data was shorter if sent via email or 
USB (median 86, 25th, 75th centile 20–405 days), but was 
longer if shared via an online platform (median 336, 25th, 
75th centile 315–357 days) (figure 2). If the data source 
was a commercial website, the median time from first 
request to data being shared was 336 (25th, 75th centile: 
273, 336) days, for lead researcher it took 169 (25th, 75th 
centile: 6.5, 495.75) days and for academic repository 23 
(25th, 75th centile: 20, 221.5) days (figure 3).
Characteristics of trials received versus not received
In a comparison between positive, negative and non- 
responders, there was evidence of a difference in year 
of study publication (p=0.027). Non- responses tended 
to be from newer studies (median (25th, 75th centile): 
2005 (2000, 2008)) compared with positive (2003 (1999, 
2007)) and negative responses (2002 (1999, 2005)). 
However, there was no evidence to suggest an association 
between year of study publication and whether IPD were 
eventually shared (data shared median year 2003 (1999, 
2007) vs data not shared 2004 (2000, 2008), p=0.29). 
Median (25th, 75th centile) sample size for trials where 
data were shared (969 (349, 4444)) was larger than those 
not shared (344 (96, 1405), p=0.0002). However, there 
was no strong evidence that study size was associated with 
positive (973 (349, 4444)), negative (453.5 (157, 1101)) 
or no response (286 (68, 1439), p=0.061) from study 
authors. Trials sponsored by the pharmaceutical industry 
were less likely to be shared compared with those spon-
sored by an academic institution or another source (17% 
vs 46%, p<0.0001).
Quality of data shared
The quality of the data shared with the two studies was 
mixed. Both studies found that on more than one occa-
sion data were sent missing key variables (eg, randomisa-
tion allocation) that had been requested in the original 
application. This meant that further contact with the 
lead researcher was required to confirm why this data 
was missing and whether it was available for sharing. This 
Figure 1 Flow diagram—contacting authors and obtaining 
data. CI, Chief Investigator.
Table 1 Reasons given by researchers for not sharing data
Reason for not sharing data N=86
Operational constraints 19
Data not available 13
Lead researcher retired/left field of study 10
Lack of communication after initial positive response 9
Company policy is to only share data from studies 
approved by EU and US regulatory agencies on or 
after 01/01/2014
7
No reason given 7
Informed consent procedures 6
Unsure whether to share data 5
Lead researcher unable to take project on/too busy 
to collaborate
4
Electronic databases no longer exist 2
Contract issues 2
Policy not to release IPD 1
Lack of enthusiasm for our pooling projects 1
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was a time- consuming issue and also led to one trial being 
excluded as it could not be analysed. Occasionally, data 
were also sent with the variable headings and codes written 
in another language, without a data dictionary. This made 
it harder to identify the variables needed for the studies 
and increased the time it took to merge with the other 
IPD. It is also possible that this may have led to incorrect 
assumptions being made when converting the data into 
a standard format. Another approach used was to share 
all the trial’s data in its raw format. If shared with a well- 
written data dictionary, this was not a problem, however, 
this was not always the case. One message that both proj-
ects discerned from this process is that even though inclu-
sion of a well- written and linked data dictionary is key in 
data sharing, this is variably done in practice.
Mechanisms of data sharing
The various mechanisms available for sharing data and 
the advantages and disadvantages associated with them 
are given in table 2. In some cases, data are shared 
directly with, and analysed by, the researcher. A number 
of pharmaceutical companies have committed to sharing 
their data via hosted servers: Clinical Study Data Request 
data repository,20 Yale University Open Data Access 
project.21 In contrast to other sharing methodologies, 
analyses are performed on the host server with analyses 
having to be performed using specified software (SAS or 
Stata).
IPD in main publication
IPD may be published as part of the primary publication 
although this is only feasible for small trials. For example, 
data from Graf’s trial22 were extracted from the publica-
tion and reformatted into an analysable dataset.
Published data on the web
Data from completed trials may be published online so 
that they can be accessed free of charge, with no appli-
cation to the data holder required. Data from the IST 
trial have been published in this way along with a data 
dictionary, which describes the dataset, including vari-
able names and codes.23 The trial dataset was downloaded 
directly from the supplementary material of the publica-
tion and was immediately ready to analyse.
Researcher provides data on request
Researchers may store data at their institution and oversee 
the data sharing process each time there is a request. 
Typically, this required an email to the lead researcher, 
including details about the study. If agreed, transfer of 
data was made under a data sharing agreement with signa-
ture by both the data holder and the user. The researcher 
then provided the data in an analysable format such as 
an Excel spreadsheet or SPSS data file. In most cases, a 
description of the dataset was provided along with the 
data. Researchers were usually willing and able to provide 
answers to follow- up queries.
Purchase of a CD of data
IPD may be on a CD/DVD that can be bought on- line. 
The data from the National Institute of Neurological 
Disorders and Stroke (NINDS) alteplase trial24 was shared 
by this method. Once the data holder had agreed to share 
their data, the encrypted CD was sent by recorded post.
Academic collaboration data repository
A number of academic collaborations exist to facilitate 
data sharing of randomised controlled trials in a partic-
ular disease area. The collaboration is approached via 
email and an on- line application form; the form requests 
details of the study’s hypothesis, analysis methods, which 
trials are required, and contact details of those wishing 
to have access to the data. The application is reviewed 
by the collaboration’s steering committee and, following 
approval, the data are provided in an analysable format. 
Examples include the NINDS25 and NHLBI26 reposi-
tories and the Alzheimer’s Disease Collaborative Study 
(ADCS).27 Some repositories include IPD without rando-
misation details so that on- treatment analyses may not be 
possible, for example, VISTA.28
Figure 2 Boxplot showing the time, in days, from first data 
request sent to receiving the data, by method of sharing.
Figure 3 Boxplot showing the time, in days, from first data 
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Commercial website
A number of pharmaceutical companies share their data 
via externally hosted servers: Clinical Study Data Request 
data repository ( www. clin ical stud ydat arequest. com),20 
Yale University Open Data Access project (https:// yoda. 
yale. edu).21 Examples include the PRoFESS and JASAP 
trials. Access is requested via an on- line application form, 
this requiring information on the study’s overview, ratio-
nale, aims and analysis methods, plans for dissemination 
of results and names of those wishing to access data. Once 
approved, a three- way contract between the commercial 
site, the company who own the data and the institution 
wishing to obtain the data is required. The process of 
negotiating the contract took several months, after which 
access to the remote analysis platform was granted. Some 
time was needed to set up access to the system and for 
the data user to become familiar with it. Statistical anal-
ysis code (written using SAS V.9.3 or V.9.4, or Stata V.15) 
was uploaded and run on the remote server. Download 
of results (typically point estimates, CIs and significance 
values) had to be approved by the data- owning company 
(presumably to prevent a direct export of the IPD). 
Approval could take a few hours to a few days, after 
which the results could be exported. During the studies, 
one website (https:// yoda. yale. edu) changed the host 
statistical software from SAS to Stata requiring statistical 
analysis software to be re- written. In the case of another 
website ( www. clin ical stud ydat arequest. com), two of the 
pharmaceutical companies that had agreed to share 
data with one of the studies decided to withdraw all data 
from the repository, causing issues with data access and 
required revision of the original contracts.
DISCUSSION
The ongoing OA- Cog and OA- Prevention studies require 
data from completed trials to be shared. Despite diffi-
culties in accessing data, there were researchers who 
Table 2 Methods for sharing individual patient data
Method of data sharing Example(s) Advantages Disadvantages N
IPD published in main 
publication
GRAF22 Free. No need to contact lead 
researcher. No effort required 
by data owner once data are 
published.
Feasible for smaller studies only. No formal 
support by lead researcher.
1
IPD published on web IST aspirin/heparin23 Free. Quick and easy to access. 
No application required. No effort 
required by data owner once data 
are published.
No formal support by lead researcher. 1
Lead researcher holds 





Free. Minimal resources required 
once dataset has been prepared 
for sharing. Lead researcher has 
complete control over who the data 
is shared with.
Requires active participation by lead 
researcher, that is, they need time to share 
data and approve each request. Assumes 
lead researcher can still be contacted 
(ie, not retired or dead). Quality of data 
and accompanying materials shared are 
variable.
46
Purchase CD of data National Institute of 
Neurological Disorders and 
Stroke (NINDS) alteplase24
Minimal resources required once 
dataset has been prepared for 
sharing.






National Heart, Lung, and 
Blood Institute (NHLBI)26
Short application process. 
Responses to requests are usually 
quick. Application process allows 
more control over who has access 
to data. Once data has been 
prepared, minimal further input is 
required from the data owner.
NINDS, NHLBI require evidence of 
Research Ethics Committee approval or 
waiver. IPD may not be complete.
14
Commercial website Clinical study data request.
com.31 Merck.32 Yale 
University Open Data Access 
(YODA) Project33
Apply for data from multiple 
companies.
Pharmaceutical companies can 
share data from their clinical trials 
via an independently monitored 
online system.
Long application process. Long waiting 
time for responses. Data needs to be 
analysed within the repository, this 
requiring upload of SAS analysis code. 
Often the platform only allows access 
to one statistical analysis software 
package making the data inaccessible to 
researchers without the necessary skills. 
Companies choose what data to share. 
Complicated, technically challenging and 
time- consuming process. Assumes that 
remote analyses will give the same results 
as those obtained locally.
18
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were enthusiastic and forthcoming with support for our 
studies and with sharing their data for 78 trials. There are 
now several different mechanisms for data sharing avail-
able to researchers, a number of which were utilised to 
share data with our studies. Unfortunately, there was a 
high non- response rate with 149 (48%) lead researchers 
not responding to an email invitation despite multiple 
attempts to make contact. A large number of researchers 
also declined to share the data from their completed trial 
with the studies.
The difficulties we experienced have been encountered 
by others conducting research projects that require IPD 
from completed trials to be shared. For instance, Fleetcroft 
et al9 reported that of 30 eligible trials, 6 did not have avail-
able contact information for the lead researcher. Of the 
remaining 24, 18 (75.0%) did not respond and 5 (20.8%) 
declined to share their data. This could indicate that data 
sharing is not a high priority for many researchers. It is 
now expected that researchers should make available a 
copy of their published trial data when requested. Jour-
nals, such as the BMJ,4 now require researchers to make 
their trial data available for sharing in order for the 
primary results to be published. In addition, some also 
require that authors include a data availability statement 
within the final publication (PLoS5). Additionally, funding 
bodies such as the US National Institutes of Health and 
UK Medical Research Council1 2 also require researchers 
to agree to share their data within a given timeframe of 
completion of the trial before funding is granted. Such 
policies will help with future trials, but do not incentivise 
researchers of older trials to share their data.
Non- response from lead researchers was a major barrier 
to accessing IPD from trials. It may help that journals now 
require a contact email address with every publication. 
However, this does not solve the problem, as these studies 
have discovered. While the general consensus is that IPD 
from trials should be made available for sharing, but in 
reality requests for data are often missed or ignored. It is 
important that researchers are able to access older data. 
If the lead researcher moves on it should be the respon-
sibility of the institution to continue support for poten-
tial data sharing. Ideally, it would be mandatory for the 
data custodian’s contact details to be made available in 
the primary publication and possibly in the trial’s registry 
information. Lack of resources for preparing data for 
sharing (table 1) is a common reason not to share IPD, 
as also seen in a survey of trialists.10 Some methods for 
sharing IPD require few resources for the data owner 
once the initial effort of preparing the data for sharing 
is done, for example, when utilising commercial websites 
and academic trial repositories. Storing the data within 
a repository can also take the burden of approving a 
request away from the lead researcher. However, this 
can be costly and may not be appropriate for all trial-
ists. Resources should be set aside to enable proper 
archiving and sharing of data to take place once a trial 
is completed. To help trialists, it would be beneficial for 
a universal set of standards for data preparation, storage 
and sharing to be developed and promoted by organisa-
tions that mandate data sharing. Another concern many 
researchers have is that data from their study may not be 
used appropriately. It is the responsibility of the requester 
to provide full details regarding why the trial data are 
required; how it will be used and stored; how it will be 
published and whether the trialists will be co- authors and 
how and when it will be destroyed. A formal data sharing 
agreement/contract should be used for data security 
purposes. Patients may also have concerns about how 
their data will be used in the future. It is vital that consent 
from patients includes information about whether their 
data may be shared with other researchers and in what 
context. The MRC have published guidance for trialists 
on data sharing and informed patient consent.20
Strengths and limitations
A strength of this research is that both studies identi-
fied a large number of eligible trials across two separate 
disease areas, resulting in a large number of researchers 
being contacted. In addition, the requested trials had 
both academic and commercial sponsors, no restric-
tion on country of origin and covered a wide timeframe 
(1985 to 2017); therefore, our results are likely to reflect 
a common experience in data sharing in vascular and 
dementia research. Limitations include using only email 
or letter to contact authors due to available resources. 
Telephone or face to face contact methods were not 
utilised and might have resulted in a different outcome 
for some trials. Next, it was not possible to survey non- 
responders to data requests, so any potential reasons for 
this should be considered as speculation. This is unfortu-
nate, as it means that the true barriers to data sharing are 
not, at this moment in time, fully known.
CONCLUSION
In summary, there are multiple hurdles that still need 
to be overcome in order to facilitate more collaboration 
and sharing between researchers. Lack of response from 
researchers and unwillingness to share data make pooling 
studies such as these difficult to deliver in practice. Based 
on our experiences, data sharing still appears to depend 
on the enthusiasm of the lead researcher, despite it being 
widely agreed that IPD should be easier available. This 
troubling trend not only means that the results of trials 
cannot be checked by an independent researcher but 
that further patients can be subjected to experimental 
treatments when the data are already available. Patients 
have taken a risk in volunteering their time to partici-
pate in research and as researchers we owe it to them to 
gain as much knowledge as possible from the data they 
have provided. If the patient has consented to further 
use of their data, then the researcher has a responsibility 
to ensure this is done. However, whether expectations 
by funders and journals for investigators and authors to 
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